Anti-D

The National Blood Authority (NBA) released the Guidelines on the Prophylactic Use of Rh D Immunoglobulin (Anti-D) in Obstetrics in 2003, with the aim of providing clinical guidance on antenatal prophylaxis. These guidelines also addressed supply constraints at the time of publication by including a staged implementation process for a full antenatal prophylaxis program in Australia.

In October 2016, the NBA and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) agreed to collaborate to develop a new evidence-based guideline on the prophylactic use of Rh D immunoglobulin (Anti-D) in maternity care.

The development of the guideline is being overseen by a multi-disciplinary Expert Reference Group (ERG) with expertise from a range of clinical settings to ensure they reflect current evidence and best clinical practice.

Expertise on the ERG includes:

  • Obstetricians and Maternal fetal medicine experts
  • Neonatology
  • General Practitioners
  • Haematologists
  • Private pathology
  • Midwives
  • Australian Red Cross Blood Service
  • Consumers/patients
  • Systematic review and guideline development support
  • Government

The ERG finalised the research protocol in July 2018 and the systematic review is underway. The draft guideline will be subject to an open public consultation process before being finalised in mid-2019.

The new guideline will retain the existing guideline’s policy intent for a national Anti-D antenatal prophylaxis program in addition to providing clinical guidance. Any impact of the evidence findings on the existing prophylaxis program will be considered by the NBA and the Jurisdictional Blood Committee.